Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

New Gabapentinoid Warning Labels

Michele B. Kaufman, PharmD, BCGP  |  January 23, 2020

In late December 2019, the U.S. Food and Drug Administration (FDA) announced that it will require new warning labels for gabapentinoids. These labels will address the risk of serious respiratory distress leading to death in patients who combine the treatment with an opioid. This change is based on a review of multiple sources, including case reports submitted to the FDA and data published in the medical literature.

Combining gabapentinoids with opioids or other drugs known to depress the central nervous system increases the risk of respiratory distress or death. Patients at risk for this reaction include individuals who have an underlying respiratory impairment, such as patients with chronic obstructive pulmonary disease and the elderly. Medications affected by this warning include gabapentin (brand names: Neurontin and Gralise), gabapentin enacarbil (a gabapentin pro-drug under the brand name Horizant), pregabalin (brand names: Lyrica and Lyrica CR) and generic versions of gabapentinoids.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Background: The FDA evaluated drug use, which showed an increased prescription usage of gabapentinoids. Between 2012 and 2016, the FDA estimated the number of patients who filled a gabapentin prescription increased from 8.3 million to 13.1 million annually. Additionally, the number of patients who filled a pregabalin prescription increased from 1.9 million to 2.1 million annually. Data collected from a 2016 office-based physician survey showed about 14–19% of patient encounters involving a gabapentinoid also involved opioids.

If prescribing gabapentinoids, healthcare professionals should start the treatment at the lowest dose. Monitor patients for symptoms of respiratory depression and sedation when co-prescribing an opioid or other central nervous system depressant, such as benzodiazepines. Healthcare professionals should be aware of the potential additive effects of all central nervous system depressants, start with low doses, and slowly titrate doses.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Patients should be made aware of the potential for central nervous system and respiratory depression. Such symptoms include dizziness, somnolence and the potential for impaired ability to drive or operate complex machinery.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

Reference

  1. U.S. Food and Drug Administration. FDA in brief: FDA requires new warnings for gabapentinoids about risk of respiratory depression. 2019 Dec 19.

Share: 

Filed under:Uncategorized Tagged with:Drug SafetyFDAgabapentinoidsU.S. Food and Drug Administration (FDA)

Related Articles

    7 Tools to Identify Depression

    August 1, 2014

    Why screening for depressive symptoms in patients with arthritis is needed

    Neurontin Prescriptions Surge Amid Opioid Crisis

    January 4, 2018

    (Reuters Health)—Prescriptions for nerve pain medicines like Neurontin and Lyrica have more than tripled in recent years, driven by increased use among chronically ill older adults and patients already taking opioids, a U.S. study suggests. The proportion of U.S. adults prescribed Neurontin and other drugs in the same family of medicines climbed from 1.2% in…

    Depression in Rheumatoid Arthritis

    November 1, 2012

    Examining the psychological and health-related comorbidities of rheumatoid arthritis patients with depression

    FDA Provides 2020 Rheumatology Drug Update

    December 17, 2020

    Three FDA representatives discuss new drug indications, safety precautions and label changes, & an emergency program to rapidly evaluate existing immunomodulating therapies for use in COVID-19 patients.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences